Ardelyx, Inc. (ARDX)

CIK 0001437402 · Healthcare · Biotechnology

Recent Filing Index

Form Filed Qtr End F_Period 8K: Earnings Release
Latest Q2-2026 8-K (2026-08-06) · 99.1 · 99.2
Q1-2026 8-K (2026-04-30) · 99.1 · 99.2
Latest FY-2025 8-K (2026-02-19) · 99.1 · 99.2  |  8-K (2026-01-08)
Q3-2025 8-K (2025-10-30) · 99.1
Q2-2025 8-K (2025-08-04) · 99.1
Q1-2025 8-K (2025-05-01) · 99.1
FY-2024 8-K (2025-02-20) · 99.1  |  8-K (2025-01-13)
Q3-2024 8-K (2024-10-31) · 99.1
Q2-2024 8-K (2024-08-01) · 99.1
Q1-2024 8-K (2024-05-02) · 99.1
FY-2023 8-K (2024-02-22) · 99.1  |  8-K (2024-01-08)
Q3-2023 8-K (2023-10-31) · 99.1

Filing Summary

Report Name | Notes Fiscal Period (Annual) Fiscal Period (Quarter)
Cover
Audit Information
—
Statements
Balance Sheets
Balance Sheets (P)
Condensed Statements of Operations and Comprehensive Income (loss)
—
Statements of Operations and Comprehensive Loss
Condensed Statements of Changes In Stockholders' Equity
—
Statements of Cash Flows
Statements of Stockholders' Equity
—
Notes
Accrued Expenses and Other Current Liabilities
—
Borrowing
Cash, Cash Equivalents and Investments
—
Cash, Cash Equivalents and Short-term Investments
Collaboration and Licensing Agreements
Commitments and Contingencies
Contingencies
—
Cybersecurity Risk Management and Strategy Disclosure
—
Deferred Royalty Obligation Related To The Sale of Future Royalties
Derivative Liabilities
Equity Incentive Plans
Equity Incentive Plans?
—
Equity Incentive Plans​
—
Fair Value Measurements
Geographic Information and Concentrations
—
Income Taxes
—
Insider Trading Arrangements
Insider Trading Policies and Procedures
—
Inventory
Leases
Nature of Operations
Net Income (loss) Per Share
—
Net Loss Per Share
Organization and Basis of Presentation
Organization and Basis of Presentation?
—
Pay Vs Performance Disclosure
Product Revenue, Net
—
Property and Equipment, Net
—
Restructuring
—
Revenue
Segment Reporting
Stockholders' Equity
Subsequent Events
—
Summary of Significant Accounting Policies
—